D.E. Shaw & Co
TARA icon

D.E. Shaw & Co’s Protara Therapeutics TARA Stock Holding History

D.E. Shaw & Co’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.5K Buy
+11,113
New +$52.9K ﹤0.01% 4709

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

D.E. Shaw & Co's TARA Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Protara Therapeutics (TARA) in Q2 2026: 11,113 shares worth $42.5K. The stake represents ﹤0.01% of the portfolio and ranks #4709 among its holdings.

120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • D.E. Shaw & Co held 11,113 shares of Protara Therapeutics worth $42.5K as of Q2 2026.
  • Protara Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4709 holding.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.